Epstein-Barr Virus and Human Disease

Front Matter....Pages i-xxxi
Front Matter....Pages 1-1
Epstein-Barr Virus-Associated Lymphoid and Epithelial Lesions Occurring in the Life Cycle....Pages 3-11
Anti-EBV Titers and the Application of a Prognostic Score to North American Patients with Nasopharyngeal Carcinoma....Pages 13-19
Nasopharyngeal Carcinoma in Yugoslavia: Geographical Distribution, Clinical, Pathological and Virological Data....Pages 21-24
A Preliminary Analysis of HLA Studies on Multiple NPC Cases among Siblings from the People’s Republic of China, Hongkong, Singapore and Malaysia....Pages 25-29
Prognostic Significance of Serial EBV Antibody Titers in Treated Nasopharyngeal Carcinoma Patients....Pages 31-37
EBV-Associated Antibodies and Other Antibodies in Nasopharyngeal Cancer Patients before and after Radiotherapy....Pages 39-41
IgA/EA: Prognosis Marker for Relapse among NPC Patients with Complete Remission after Radiotherapy....Pages 43-45
Epstein-Barr Virus Infection in Families with a Childhood Index Case of Infectious Mononucleosis....Pages 47-48
Antibodies to EBV Specific Enzymes in the Chronic EBV Syndrome....Pages 49-52
Presence of Monoclonal and Oligoclonal B-Cell Proliferation in Fatal Infectious Mononucleosis....Pages 53-54
Comparison of EBV Serological Reactivities between Two Groups of NPC Patients Surviving More Than 7 Years or Dead 2 Years after Diagnosis....Pages 55-57
Application of EBV-Serology to the Clinical Monitoring of Patients with Nasopharyngeal Carcinoma....Pages 59-61
A Prospective Study of Antibodies to Epstein-Barr Virus DNase and Viral Capsid Antigen (IgA) in the Prognosis of Nasopharyngeal Carcinoma....Pages 63-65
Anti-EBV DNase Antibody as a Marker for Prospective Study of Nasopharyngeal Carcinoma....Pages 67-69
HLA -A, -B and -DR Antigens in North African Patients with Nasopharyngeal Carcinoma....Pages 71-72
Autoantibodies Against the Epstein-Barr Virus Receptor (EBVR) in Sera from Rheumatoid Arthritis Patients....Pages 73-75
Front Matter....Pages 77-77
Evidence for Association of Epstein-Barr Virus with Malignant Lymphoepithelial Lesion of Salivary Gland....Pages 79-83
Cancer Risks and EBV Antibody Patterns in NPC Families....Pages 85-89
EBV Related B Cell Lymphoproliferative Disease after T Depleted Mismatched Bone Marrow Transplantation....Pages 91-95
T Cell Lymphomas in Patients with Chronic EBV Infection....Pages 97-100
Front Matter....Pages 77-77
Morbidity of Epstein-Barr Virus Infection in Children....Pages 101-104
Chronic active Epstein-Barr virus infection in children: heterogeneity in immune defects and EBNA-antibody pattern....Pages 105-110
P3HR-1-Like Nontransforming Virus in Saliva and Peripheral Blood Lymphocytes in Chronic Active EBV Infection....Pages 111-115
Development of Two Monoclonal B-Cell Lymphomas in a Patient with Wiskott-Aldrich Syndrome....Pages 117-118
Detection of Epstein-Barr Virus DNA in Saliva of Patients with Aids and Related Disorders....Pages 119-120
Detection in Normal Tonsils of a Novel B Lymphocyte Population with a Burkitt-Like Phenotype....Pages 121-122
Epstein-Barr Virus in the Lower Respiratory Tract....Pages 123-124
Semiquantitative Analysis of Oropharyngeal EBV Shedding in Various Populations by Dot Blot Hybridization....Pages 125-126
Prevalence of EBV in Household Contacts of Patients with Nasopharyngeal Carcinoma....Pages 127-129
Changes in Lymphocyte Populations in Nasopharyngeal Carcinoma (NPC) Following Primary Radiotherapy with Subsequent a 2 -Interferon (IFN)-Therapy....Pages 131-133
Some Questions Raised by Studies on Greenland Eskimos....Pages 135-136
Front Matter....Pages 137-137
Effects of S-adenosylhomocysteine and Analogs on Epstein-Barr Virus (EBV)-Induced Transformation, EBV DNA Methylation and Gene Expression....Pages 139-143
Mapping EBV Early Antigens in Human Cells after Microinjection of Subgenomic DNA Clones....Pages 145-149
Regulation of EBV Lytic Cycle Genes: MS-EA, a Trans-Activator of Gene Expression....Pages 151-155
An EBV Early Promoter is Activated by Two Viral Encoded Transacting Eactors EB1 and EB2....Pages 157-161
Regulation of EBV Promoters....Pages 163-167
Induction of Epstein-Barr Virus Genes in Raji Cells by 12-O-Tetradecanoyl Phorbol-13-Acetate Requires Ongoing Protein Synthesis....Pages 169-173
Gene Expression in the BamHI E Region of EBV....Pages 175-177
Development of a Set of EBV-Specific Antigens with Recombinant Gene Technology for Diagnosis of EBV-Related Malignant or Nonmalignant Diseases....Pages 179-182
Detection of EBV DNA in Nude Mouse Passaged Nasopharyngeal Carcinoma (NPC) Tissues....Pages 183-187
Front Matter....Pages 137-137
Detection of Epstein-Barr Virus DNA in Nasopharyngeal Biopsies....Pages 189-190
Plasmid Stabilization in Drosophila Cells Expressing EBNA1....Pages 191-192
Identification and Characterization of Early Genes Involved in Epstein-Barr Virus Replication....Pages 193-194
Front Matter....Pages 195-195
Disruption of Latency by a Fragment of Rearranged EBV DNA: Evidence for Host Cell Regulation....Pages 197-206
Variation in Epstein-Barr Virus Strains....Pages 207-210
Identification and Characterization of Regulatory Proteins of EBV....Pages 211-215
Characterization of the EBV Thymidine Kinase....Pages 217-222
Characterization of an Epstein-Barr Virus (EBV) Membrane....Pages 223-227
Epstein-Barr Virus Protein (LMP) Expression is Enhanced by Serum, TPA or Butyrate....Pages 229-233
Use of Synthetic Oligopeptides for the Identification and Characterization of Epstein-Barr Viral Membrane Proteins....Pages 235-239
Phenotypic Characterization of C15, A Nude-Mouse Grown NPC Tumor....Pages 241-245
EBNA-1 Binds Specifically to Plasmids Containing a Synthetic 29 BP Binding Site....Pages 247-248
Expression of the C-Terminal Part of an EBNA 2 Variant (2B) and Generation of Specific Sera....Pages 249-250
Characterization of a major EA-D component of the EBV-induced EA complex....Pages 251-252
Two Monoclonal Antibodies against Epstein-Barr Virus Proteins....Pages 253-254
Expression of the EBV-Encoded Membrane Protein (LMP) in Virally Transformed Cells....Pages 255-256
Identification of EBV-Induced Polypeptides with Sera from Patients with SLE, RA or IM....Pages 257-259
Computerized Chou-Fasman secondary structure analysis of EBV-coded membrane-bound proteins....Pages 261-262
Cross Reactivity between EBV and Herpes Simplex Virus....Pages 263-264
Front Matter....Pages 265-265
Biological Aspects of Epstein-Barr Virus-Induced B-Cell Immortalization....Pages 267-274
Front Matter....Pages 265-265
Comparison of Interleukin-1 with Endogenous B-Cell Factors for Effects on Lymphoma Cell Growth After EBV Conversion....Pages 275-279
A Nude-Mouse-Grown NPC Tumor Produces Interleukin-1....Pages 281-286
Autoantibody Production by Human B Lymphocytes which Spontaneously Proliferate....Pages 287-291
Distribution of Epstein-Barr Virus Strains with Different EBNA 2 Genotypes in Burkitt-Endemic Areas....Pages 293-297
Biological Properties of Epstein-Barr Virus Recovered from Epithelial Cells Transfected with DNA Prepared from a Nasopharyngeal Carcinoma-Derived EBV....Pages 299-303
Characterization of the Suppressor Effect of B-95–8 Virus on EA Inducing Capability of P3HR-1 Virus....Pages 305-307
Epstein-Barr Virus Genome Activation in Latently Infected Cells by Calcium Ionophores....Pages 309-312
Effects of Non-Ionizing Radiation on EBV Non-Producing Cells....Pages 313-316
Cytofluorometric Study of Epstein-Barr Virus Receptor Expression on Human T Lymphocyte Populations....Pages 317-321
Isolation of a Normal B Cell Subset with a Burkitt-Like Phenotype & Examination of its Interaction with EB Virus....Pages 323-327
Superinfecting Activity of the B95–8 Isolate of Epstein-Barr Virus....Pages 329-330
Polyclonal Activation of B Lymphocytes after EB Virus Infection....Pages 331-332
Front Matter....Pages 333-333
Cellular Controls over EBV Infection....Pages 335-341
HLA-Antigens and Cell-Mediated Immunity to EBV....Pages 343-347
Interleukins and Interferons during EBV Infection....Pages 349-353
Primary Killer-Cell Defect in Patients with Chronic Active Epstein-Barr Virus (EBV) Infection and Acquired Hyper IgG1....Pages 355-359
Lymphatic Tissue Response to Persistent Active Virus Infections in Immune Deficiency....Pages 361-366
A Reevaluation of EBV-Specific T Cell-Mediated Immunity in Malaria-Endemic and Non-Endemic Regions of Papua, New Guinea....Pages 367-371
Synergism between Epstein-Barr Virus and B Cell Growth Factor....Pages 373-377
Monocytes and a Monocyte Product Regulate Epstein-Barr Virus-Induced B Cell Activation....Pages 379-383
Front Matter....Pages 333-333
Inhibition of Interleukin-2 Synthesis by Infectious Mononucleosis-Associated IgG Blocking Factor....Pages 385-387
Induction of Nonspecific Suppressor Cells by Different Epstein-Barr Virus Antigens....Pages 389-392
Stimulation of EB Virus-Specific Helper T Cells by Burkitt’s Lymphoma and Lymphblastoid Cell Lines....Pages 393-394
Raji Cells Release Soluble Factors Which Modulate NK Activity of Human Peripheral Blood Lymphocytes....Pages 395-396
Frequencies of Reactive Cells to Autologous Lymphoblastoid Cells in Males with X-Linked Lymphoproliferative Syndrome....Pages 397-398
Autoantibody Generation during Infectious Mononucleosis....Pages 399-400
Epstein-Barr Virus Serology: Specificities of Sera Against EBNA 1 and EBNA 2....Pages 401-403
X-Linked Lymphoproliferative Patient Antibody Response to a Synthetic Peptide of Epstein-Barr Nuclear Antigen....Pages 405-406
Differential Expression of EB-Viral and Cellular Surface Markers on Burkitt Lymphoma and Lymphoblastoid Cell Lines....Pages 407-411
Front Matter....Pages 413-413
Role of CO-Factors in the Etiology of EBV-Related Diseases....Pages 415-421
EBV DNA Structure and Oncogene Expression in EBV-Associated Malignancies....Pages 423-428
NIH 3T3 Cell Transformation by DNAs from Lymphoma Cells and from Epstein-Barr Virus-Immortalized Human Lymphocytes....Pages 429-433
Volatile Nitrosamines in Food Samples Collected in Three High Risk Areas for Nasopharyngeal Carcinoma....Pages 435-438
Induction of Epstein-Barr Virus in Raji Cells by Plasmodium Falciparum and by Normal Red Blood Cells....Pages 439-443
An Environmental Plant Factor Enhancing Epstein-Barr Virus-Induced Events in East Africa....Pages 445-449
Chemical carcinogen enhancement of Epstein-Barr virus (EBV)-induced transformation: association with EBV genome amplification....Pages 451-452
Geopathological Coincidence of Burkitt’s Lymphoma and Endemic Kaposi’s Sarcoma in Western Kenya....Pages 453-454
Model Studies Related to Nasopharyngeal Carcinoma....Pages 455-456
Chronic HTLV-III Infection in EBV-Genome Containing B-Cell Lines....Pages 457-459
Front Matter....Pages 461-461
Preparation of an EBV Vaccine to Prevent Oncogenesis: An Update....Pages 463-467
Front Matter....Pages 461-461
Antigenic Analysis of the EBV Major Membrane Protein (gp350/gp220) Expressed in Yeast and Mammalian Cells....Pages 469-474
Expression and Analysis of EBV gp350 in the Yeast Saccharomyces Cerevisiae ....Pages 475-478
Expression of the Major Envelope Glycoprotein gp350/220 of Epstein-Barr Virus by a Recombinant Varicella Zoster Virus....Pages 479-483
Secretion of the Two Major Epstein-Barr Viral Glycoproteins (gp250/350) from Recombinant Chinese Hamster Ovary Cells....Pages 485-489
Post-Radiotherapy Adjuvant Chemotherapy of Regionally Advanced UNPC: Increase in Disease Free Survival....Pages 491-495
Inhibition of Epstein-Barr Virus Replication by 1-β-d-Arabinofuranosyl-E-5-(2-Bromovinyl) Uracil in Vitro ....Pages 497-502
Ebv-Specific Transfer Factor in the Treatment of Abdominal Burkitt’s Lymphoma in Ghana, West Africa....Pages 503-507
Circulating Interferon in EBV Infections....Pages 509-510
Inhibition of Epstein-Barr Virus Release by anti-MA Antibody....Pages 511-512
Role of CD8+ and CD8- Cytolytic Effectors in IL2 Reversal of Cyclosporin-Inhibited EBV-B-Cell Cytotoxicity....Pages 513-515
Rationale for Intravenous Gamma-Globulin Therapy of Persistent Lymphotropic Viral Infections....Pages 517-518
Back Matter....Pages 519-530